Ellipses Pharma Ltd. has agreed to in-license global rights to GENA-104, a first-in-class immuno-oncology monoclonal antibody that targets CNTN4, from Genome & Co. Ltd. Targeting CNTN4 is a new approach that blocks the CNTN4-APP checkpoint interaction on T cells, promoting tumor cell killing, with potential use in cancers that respond poorly to conventional checkpoint inhibitors.
Immvention Therapeutix Inc. has entered into a collaboration and license agreement with Novo Nordisk A/S to co-develop oral therapies for sickle cell disease and other chronic conditions.
Arrivent Biopharma Inc. has entered into an exclusive license agreement with Lepu Biopharma Co. Ltd. for MRG-007, an antibody-drug conjugate (ADC) in development for gastrointestinal cancers.